BEAM logo

BEAM THERAPEUTICS INC

BEAMNASDAQ
πŸ† #1779 by market capEarnings Feb 23US Equity
$20.90β–Ό $0.04 (βˆ’0.19%)
Market closed Β· at close
πŸ””
Track BEAM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.2%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.16B
Small Cap
πŸ“ˆRevenue Growth (YoY)
120.0%
High Growth
πŸ“ŠGross Margin
100.0%
High
πŸ’΅FCF Margin
-271.6%
Thin
βš–οΈP/S Ratio
14.8x
Expensive
Otter Score
60
Fair
No chart data available for BEAM.

Trading Snapshot

Day Range
$20.54 – $22.10
52-Week Range
$20.44 – $38.26
Volume (shares)
3,886,582
Avg Volume (shares)
β€”
Shares Outstanding
103.5M
Next Earnings
2027-02-23

Fundamentals Snapshot

Annual Revenue
$140M
Last Q Revenue
$307,000
P/E Ratio
-20.9
P/S Ratio
14.8x
EPS (TTM)
$-1.02
Dividend Yield
0.00%
Dilution (1yr)
+27.5%
BEAM logo

BEAM THERAPEUTICS INC

BEAM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$140Mβ–² +120.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
84.0%β–Ό βˆ’117.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$384Mβ–Ό βˆ’7.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$360Mβ–² +1.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
104.9Mβ–² +27.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1Mβ–Ό βˆ’$119M YoY
StockOtter Β· stockotter.space

About BEAM THERAPEUTICS INC

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100
Analyst data unavailable.

Latest News & Updates

Seeking AlphaΒ·5d ago

Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

Seeking AlphaΒ·10d ago

Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up

Beam Therapeutics receives a Buy rating, driven by promising data across AATD, GSDIa, and SCD, and robust funding. BEAM's risto-cel SCD therapy shows strong efficacy but faces market skepticism due to challenging treatme

Zacks Investment ResearchΒ·11d ago

BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study

Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.

GlobeNewsWireΒ·12d ago

Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease

BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary Safety Endpoints at

GlobeNewsWireΒ·18d ago

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom

Zacks Investment ResearchΒ·19d ago

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.